Tyrosine kinase SRC-induced YAP1-KLF5 module regulates cancer stemness and metastasis in triple-negative breast

Hailin Zou1, Juan Luo1, Yibo Guo1

  • 1Scientific Research Center, The Seventh Affiliated Hospital of Sun Yat-Sen University, No. 628 Zhenyuan Road, Shenzhen, 518107, Guangdong, People's Republic of China.

Insights

SRC kinase drives cancer stemness and metastasis in triple-negative breast cancer (TNBC) by activating a YAP1-KLF5 module. Targeting this module offers a potential therapeutic strategy for TNBC.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • SRC is an oncogene implicated in tumor progression, but its role in cancer stemness and metastasis is unclear.
  • Triple-negative breast cancer (TNBC) is aggressive, necessitating research into its underlying mechanisms.

Purpose of the Study:

  • To elucidate the mechanism by which SRC regulates cancer stemness and metastasis in TNBC.
  • To identify key downstream mediators of SRC in TNBC progression.

Main Methods:

  • Investigated SRC expression in TNBC tissues and correlated it with malignancy.
  • Utilized transcriptomic and proteomic analyses to identify SRC targets.
  • Examined the role of the YAP1-KLF5 module in SRC-mediated cancer stemness and metastasis in vitro and in vivo.

Main Results:

  • SRC overexpression correlates with TNBC malignancy and drives cancer stemness and metastasis.
  • SRC phosphorylates YAP1, promoting its interaction with KLF5 to form a YAP1/TEAD-KLF5 complex.
  • This complex enhances TEAD-mediated transcription, independent of Hippo kinases, driving stemness and metastasis.
  • Disrupting the YAP1-KLF5 module significantly reduces SRC-induced cancer stemness and metastasis.

Conclusions:

  • A novel YAP1 tyrosine phosphorylation-dependent YAP1-KLF5 oncogenic module mediates SRC-induced cancer stemness and metastasis in TNBC.
  • Targeting the YAP1/KLF5-mediated transcription pathway presents a promising therapeutic strategy for SRC-driven TNBC.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.0K
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
4.3K
Metastasis02:30

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.6K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.8K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.9K